Brief: China Regenerative Medicine International Expects FY Profit To Increase At Least 28%
25/03/2026 15:30
March 25 (Reuters) - China Regenerative Medicine International Ltd 8158.HK: EXPECTS PROFIT ATTRIBUTABLE TO INCREASE AT LEAST 28% FOR FY2025 EXPECTED INCREASE IN PROFIT MAINLY DUE TO INCOME TAX CREDIT RECOGNIZED IN FY2025 Further company coverage: 8158.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Regenerative Medicine International
See all newsBrief: China Regenerative Medicine International Expects FY Profit To Increase At Least 28%
Brief: China Regenerative Medicine International Says Yan Shibin Will Be Appointed As CFO
Brief: China Regenerative Medicine International Posts H1 Revenue Of HKD59.78 Mln
Brief: China Regenerative Medicine International Posts FY Loss Attributable HK$107.7 Mln
Brief: China Regenerative Medicine International Says Subscription Of Increased Registered Capital